On May 3, 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease reported additional preclinical data from the company’s fibrosis portfolio including data on lead asset RXC007, and Discodin Domain Receptor (DDR) 1/2 inhibitors will be presented both orally and in a poster, at The Resistant Tumour Microenvironment, Keystone Symposia (7-10 May 2022, Vancouver, BC, Canada) (Press release, Redx Pharma, MAY 3, 2023, View Source [SID1234630939]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the session on Wednesday 10 th May 0830-1130am PDT: ‘Friend or Foe: Should we Target Cancer Associated Fibroblasts and the ECM?’ Redx Senior Scientist, Dr. Daniel Wilcock will discuss if targeting tumor fibrosis with small molecule inhibitors of Rho Associated Coiled Coil Containing Protein Kinase 2 (ROCK2) or DDR1/2 improves therapy response in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC).
Data presented will be from the Company’s lead fibrosis asset, RXC007 as well as the DDR discovery programme, which further complements the data set presented last year at the Extracellular Matrix Pharmacology Congress by collaboration partner, the Garvan Institute of Medical Research. In addition to Dr Wilcock’s presentation, Redx will present a poster which details the potential of RXC007 in an aggressive patient derived xenograft model of PDAC in combination with standard of care (SoC) chemotherapy, and DDR1/2 inhibition in a TNBC model in combination with anti-PD-1.
RXC007, the Company’s lead asset, is a highly potent, selective and orally-active ROCK2 inhibitor targeting multiple diseases associated with fibrosis, initially being developed for interstitial lung diseases. A Phase 2a study assessing RXC007 as a potential treatment for patients with idiopathic pulmonary fibrosis (IPF) is expected to report topline data in Q1 2024.
Details of the presentation are as follows:
Title: Targeting tumor fibrosis with small molecule inhibitors of ROCK2 or DDR1/2 improves therapy response in preclinical models of PDAC &TNBC
Session: Friend or Foe: Should we Target Cancer Associated Fibroblasts and the ECM?
Day/Date: Wednesday 10 th May, 2023 Time: 08:30-11:30 am PDT
A copy of the poster will be made available on the Company’s website following the presentation at: View Source